HeartBeam, Inc.: management transactions · United States · SEC (Form 4)

About HeartBeam, Inc.

HeartBeam, Inc. is a U.S.-based medical technology company listed on NASDAQ in the United States. Founded in 2015 and incorporated in Delaware, the company is headquartered in Santa Clara, California. From an equity-research perspective, HeartBeam fits the profile of an early-commercial-stage medtech: a small-cap company moving from regulatory development toward first market adoption, with a valuation story driven more by product execution than by current scale. For French-, Belgian- and Swiss-based investors, the key investment thesis is straightforward: HeartBeam aims to make clinically meaningful ECG monitoring available outside the hospital through a portable, cable-free platform. The company’s core business is built around proprietary 3D ECG technology. HeartBeam’s system captures cardiac electrical signals from three non-coplanar directions and uses software to synthesize a 12-lead ECG representation. The initial product is a credit-card-sized, cable-free device intended for symptom-driven recording at home or wherever the patient is located. This is designed to support arrhythmia assessment and broader cardiac monitoring, potentially helping shorten the time between symptoms and clinical interpretation. HeartBeam is also developing an extended-wear patch form factor, which suggests the platform could eventually expand beyond episodic use cases into more continuous monitoring applications. Historically, HeartBeam spent several years in R&D and regulatory preparation before reaching its most important milestone. In December 2024, the company received FDA 510(k) clearance for the HeartBeam System for comprehensive arrhythmia assessment. In December 2025, it announced another FDA clearance for its 12-lead ECG synthesis software, strengthening the company’s pathway from product development to commercialization. By early 2026, HeartBeam said it was beginning a limited commercial launch, initially focusing on preventive cardiology, concierge medicine, and direct-pay channels in the U.S. market. Competitive positioning is centered on product differentiation rather than scale. HeartBeam’s value proposition combines portability, patented technology, and the goal of delivering a 12-lead ECG outside the medical facility. That said, the company still faces the typical risks of an emerging medtech platform: customer adoption, reimbursement visibility, manufacturing and commercialization execution, and competition from established ambulatory monitoring and ECG players. The company also announced its first commercial customer, ClearCardio, in 2026, which is an important early validation of market interest, although commercial scale remains modest. Geographically, HeartBeam’s operations are overwhelmingly U.S.-centric, with its headquarters and development base in California. For European investors, that means HeartBeam should be viewed as a high-risk, high-upside NASDAQ-listed U.S. healthcare technology name, with meaningful optionality if commercialization gains traction but substantial downside if adoption or funding progress disappoints. Recent highlights include FDA clearances, initial commercialization, clinical data presentations, and the first announced commercial customer, all of which mark a transition from development story to early go-to-market execution.